(Q37202761)

18 August 2017

1 reference

title

Bortezomib in the front-line treatment of multiple myeloma (English)

1 reference

18 August 2017

Paul G Richardson

1 reference

18 August 2017

Kenneth C Anderson

1 reference

18 August 2017

Nikhil Munshi

1 reference

18 August 2017

Irene Ghobrial

1 reference

18 August 2017

Teru Hideshima

1 reference

18 August 2017

Constantine S Mitsiades

series ordinal

object named as

Constantine Mitsiades

1 reference

18 August 2017

Robert Schlossman

1 reference

18 August 2017

publication date

1 July 2008

1 reference

Expert Review of Anticancer Therapy

18 August 2017

published in

1 reference

18 August 2017

1 reference

18 August 2017

1 reference

18 August 2017

page(s)

1053-1072

1 reference

18 August 2017

cites work

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Suppression of Fas-FasL coexpression by erythropoietin mediates erythroblast expansion during the erythropoietic stress response in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

The proteasome: a suitable antineoplastic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Alternative splicing due to an intronic SNP in HMSD generates a novel minor histocompatibility antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Myeloma bone disease and proteasome inhibition therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

International staging system for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure--a retrospective analysis and recommendations for dose adjustment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Prognostic and therapeutic significance of myeloma genetics and gene expression profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Thrombosis in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Review of 1027 patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Response to bortezomib and activation of osteoblasts in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Recent major improvement in long-term survival of younger patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Stem-cell transplantation for multiple myeloma in the era of novel drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Cancer incidence and mortality in Europe, 2004

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

Impact of complete remission with intensive therapy in patients with responsive multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1053

10.1586/14737140.8.7.1053

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference